MEDICLIN AG (MED.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:MED - DE0006595101 - Common Stock
3.72 EUR
+0.18 (+5.08%)
MED gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 29 industry peers in the Health Care Providers & Services industry. MED has an excellent profitability rating, but there are some minor concerns on its financial health. MED scores decently on growth, while it is valued quite cheap. This could make an interesting combination.
1. Profitability
1.1 Basic Checks
MED had positive earnings in the past year.
In the past year MED had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: MED reported negative net income in multiple years.
Each year in the past 5 years MED had a positive operating cash flow.
1.2 Ratios
With a decent Return On Assets value of 3.85%, MED is doing good in the industry, outperforming 68.97% of the companies in the same industry.
MED's Return On Equity of 14.15% is fine compared to the rest of the industry. MED outperforms 72.41% of its industry peers.
With a decent Return On Invested Capital value of 7.06%, MED is doing good in the industry, outperforming 68.97% of the companies in the same industry.
MED had an Average Return On Invested Capital over the past 3 years of 3.46%. This is below the industry average of 6.33%.
The last Return On Invested Capital (7.06%) for MED is above the 3 year average (3.46%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.85% | ||
| ROE | 14.15% | ||
| ROIC | 7.06% |
ROA(3y)0.85%
ROA(5y)0.34%
ROE(3y)3.39%
ROE(5y)1.18%
ROIC(3y)3.46%
ROIC(5y)2.35%
1.3 Margins
Looking at the Profit Margin, with a value of 4.40%, MED is in the better half of the industry, outperforming 72.41% of the companies in the same industry.
MED's Profit Margin has improved in the last couple of years.
With a decent Operating Margin value of 8.52%, MED is doing good in the industry, outperforming 68.97% of the companies in the same industry.
MED's Operating Margin has improved in the last couple of years.
MED's Gross Margin of 84.08% is amongst the best of the industry. MED outperforms 82.76% of its industry peers.
MED's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 8.52% | ||
| PM (TTM) | 4.4% | ||
| GM | 84.08% |
OM growth 3Y67.11%
OM growth 5Y19.19%
PM growth 3Y148.06%
PM growth 5Y18.19%
GM growth 3Y0.37%
GM growth 5Y0.18%
2. Health
2.1 Basic Checks
MED has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
MED has about the same amout of shares outstanding than it did 1 year ago.
MED has about the same amout of shares outstanding than it did 5 years ago.
MED has a better debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of 1.58, we must say that MED is in the distress zone and has some risk of bankruptcy.
MED has a Altman-Z score of 1.58. This is in the lower half of the industry: MED underperforms 62.07% of its industry peers.
MED has a debt to FCF ratio of 9.63. This is a negative value and a sign of low solvency as MED would need 9.63 years to pay back of all of its debts.
MED's Debt to FCF ratio of 9.63 is in line compared to the rest of the industry. MED outperforms 51.72% of its industry peers.
MED has a Debt/Equity ratio of 1.69. This is a high value indicating a heavy dependency on external financing.
MED has a Debt to Equity ratio of 1.69. This is in the lower half of the industry: MED underperforms 62.07% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.69 | ||
| Debt/FCF | 9.63 | ||
| Altman-Z | 1.58 |
ROIC/WACC1.5
WACC4.71%
2.3 Liquidity
MED has a Current Ratio of 1.93. This is a normal value and indicates that MED is financially healthy and should not expect problems in meeting its short term obligations.
With an excellent Current ratio value of 1.93, MED belongs to the best of the industry, outperforming 86.21% of the companies in the same industry.
MED has a Quick Ratio of 1.89. This is a normal value and indicates that MED is financially healthy and should not expect problems in meeting its short term obligations.
MED has a Quick ratio of 1.89. This is amongst the best in the industry. MED outperforms 89.66% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.93 | ||
| Quick Ratio | 1.89 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 414.18% over the past year.
The Earnings Per Share has been growing by 20.79% on average over the past years. This is a very strong growth
MED shows a small growth in Revenue. In the last year, the Revenue has grown by 3.40%.
Measured over the past years, MED shows a small growth in Revenue. The Revenue has been growing by 2.19% on average per year.
EPS 1Y (TTM)414.18%
EPS 3Y157.01%
EPS 5Y20.79%
EPS Q2Q%7.67%
Revenue 1Y (TTM)3.4%
Revenue growth 3Y3.65%
Revenue growth 5Y2.19%
Sales Q2Q%7.96%
3.2 Future
Based on estimates for the next years, MED will show a very strong growth in Earnings Per Share. The EPS will grow by 20.09% on average per year.
Based on estimates for the next years, MED will show a small growth in Revenue. The Revenue will grow by 3.42% on average per year.
EPS Next Y62.2%
EPS Next 2Y28.31%
EPS Next 3Y20.09%
EPS Next 5YN/A
Revenue Next Year5.05%
Revenue Next 2Y3.88%
Revenue Next 3Y3.42%
Revenue Next 5YN/A
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
MED is valuated cheaply with a Price/Earnings ratio of 5.03.
100.00% of the companies in the same industry are more expensive than MED, based on the Price/Earnings ratio.
Compared to an average S&P500 Price/Earnings ratio of 27.19, MED is valued rather cheaply.
A Price/Forward Earnings ratio of 5.46 indicates a rather cheap valuation of MED.
100.00% of the companies in the same industry are more expensive than MED, based on the Price/Forward Earnings ratio.
MED's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 23.88.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.03 | ||
| Fwd PE | 5.46 |
4.2 Price Multiples
MED's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. MED is cheaper than 96.55% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, MED is valued cheaper than 86.21% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 3.8 | ||
| EV/EBITDA | 2.81 |
4.3 Compensation for Growth
MED's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of MED may justify a higher PE ratio.
A more expensive valuation may be justified as MED's earnings are expected to grow with 20.09% in the coming years.
PEG (NY)0.08
PEG (5Y)0.24
EPS Next 2Y28.31%
EPS Next 3Y20.09%
5. Dividend
5.1 Amount
MED has a Yearly Dividend Yield of 1.08%.
Compared to an average industry Dividend Yield of 1.45, MED has a dividend in line with its industry peers.
Compared to an average S&P500 Dividend Yield of 1.94, MED's dividend is way lower than the S&P500 average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.08% |
5.2 History
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
DPN/A
EPS Next 2Y28.31%
EPS Next 3Y20.09%
FRA:MED (1/9/2026, 7:00:00 PM)
3.72
+0.18 (+5.08%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners0.96%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap176.70M
Revenue(TTM)797.34M
Net Income(TTM)35.05M
Analysts83.33
Price Target5.87 (57.8%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.08% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)22.34%
PT rev (3m)22.34%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)6.4%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.48%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.03 | ||
| Fwd PE | 5.46 | ||
| P/S | 0.22 | ||
| P/FCF | 3.8 | ||
| P/OCF | 1.83 | ||
| P/B | 0.71 | ||
| P/tB | 0.79 | ||
| EV/EBITDA | 2.81 |
EPS(TTM)0.74
EY19.89%
EPS(NY)0.68
Fwd EY18.33%
FCF(TTM)0.98
FCFY26.32%
OCF(TTM)2.04
OCFY54.71%
SpS16.79
BVpS5.21
TBVpS4.7
PEG (NY)0.08
PEG (5Y)0.24
Graham Number9.32
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.85% | ||
| ROE | 14.15% | ||
| ROCE | 9.1% | ||
| ROIC | 7.06% | ||
| ROICexc | 9.61% | ||
| ROICexgc | 10.05% | ||
| OM | 8.52% | ||
| PM (TTM) | 4.4% | ||
| GM | 84.08% | ||
| FCFM | 5.83% |
ROA(3y)0.85%
ROA(5y)0.34%
ROE(3y)3.39%
ROE(5y)1.18%
ROIC(3y)3.46%
ROIC(5y)2.35%
ROICexc(3y)4.47%
ROICexc(5y)3.03%
ROICexgc(3y)4.72%
ROICexgc(5y)3.22%
ROCE(3y)4.46%
ROCE(5y)3.03%
ROICexgc growth 3Y64.29%
ROICexgc growth 5Y26.18%
ROICexc growth 3Y68.25%
ROICexc growth 5Y27.23%
OM growth 3Y67.11%
OM growth 5Y19.19%
PM growth 3Y148.06%
PM growth 5Y18.19%
GM growth 3Y0.37%
GM growth 5Y0.18%
F-Score8
Asset Turnover0.88
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.69 | ||
| Debt/FCF | 9.63 | ||
| Debt/EBITDA | 3.49 | ||
| Cap/Depr | 96.09% | ||
| Cap/Sales | 6.29% | ||
| Interest Coverage | 3.18 | ||
| Cash Conversion | 80.47% | ||
| Profit Quality | 132.66% | ||
| Current Ratio | 1.93 | ||
| Quick Ratio | 1.89 | ||
| Altman-Z | 1.58 |
F-Score8
WACC4.71%
ROIC/WACC1.5
Cap/Depr(3y)56.34%
Cap/Depr(5y)45.08%
Cap/Sales(3y)4.78%
Cap/Sales(5y)4.13%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)414.18%
EPS 3Y157.01%
EPS 5Y20.79%
EPS Q2Q%7.67%
EPS Next Y62.2%
EPS Next 2Y28.31%
EPS Next 3Y20.09%
EPS Next 5YN/A
Revenue 1Y (TTM)3.4%
Revenue growth 3Y3.65%
Revenue growth 5Y2.19%
Sales Q2Q%7.96%
Revenue Next Year5.05%
Revenue Next 2Y3.88%
Revenue Next 3Y3.42%
Revenue Next 5YN/A
EBIT growth 1Y281.51%
EBIT growth 3Y73.21%
EBIT growth 5Y21.8%
EBIT Next Year143.72%
EBIT Next 3Y33.62%
EBIT Next 5YN/A
FCF growth 1Y196.83%
FCF growth 3Y-17.96%
FCF growth 5Y7.78%
OCF growth 1Y96.85%
OCF growth 3Y-0.57%
OCF growth 5Y2.97%
MEDICLIN AG / MED.DE FAQ
What is the ChartMill fundamental rating of MEDICLIN AG (MED.DE) stock?
ChartMill assigns a fundamental rating of 6 / 10 to MED.DE.
Can you provide the valuation status for MEDICLIN AG?
ChartMill assigns a valuation rating of 9 / 10 to MEDICLIN AG (MED.DE). This can be considered as Undervalued.
Can you provide the profitability details for MEDICLIN AG?
MEDICLIN AG (MED.DE) has a profitability rating of 7 / 10.
Can you provide the PE and PB ratios for MED stock?
The Price/Earnings (PE) ratio for MEDICLIN AG (MED.DE) is 5.03 and the Price/Book (PB) ratio is 0.71.
What is the financial health of MEDICLIN AG (MED.DE) stock?
The financial health rating of MEDICLIN AG (MED.DE) is 4 / 10.